Management of Hyponatremia in Cirrhosis

Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment: Second Edition

Volumn , Issue , 2007, Pages 315-326

  Cárdenas, Andrés ^a   Ginès, Pere ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cirrhosis; Diuretics; Epidemiology; Hyponatremia; Neurohormonal systems

Indexed keywords

EID: 84889423727     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987476.ch26     Document Type: Chapter

References (65)

1. Arroyo V, Rodés J, Gutiérrez-Lizarraga MA et al. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976; 21:249-56.
2. Porcel A, Diaz F, Rendon P et al. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162:323-8.
3. Arroyo V, Bosch J, Gaya-Beltran J et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198-201.
4. Fernández-Esparrach G, Sanchez-Fueyo A, Ginès P et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34:46-52.
5. Ginès P, Cárdenas A, Schrier R. Liver disease and the kidney. In: Schrier R, ed. Diseases of the Kidney and Urinary Tract, 7th edn. Philadelphia: Lippincott Williams & Wilkins, 2001; 2167-203.
6. Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 1986; 314:1529-35.
7. Ayus JC, Arieff AI. Pulmonary complications of hyponatremic encephalopathy. Noncardiogenic pulmonary edema and hypercapnic respiratory failure. Chest 1995; 107:517-21.
8. Fraser C, Arieff AI. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997; 102:67-77.
9. Jung JS, Bhat RV, Preston GM et al. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci USA 1994; 91:13052-6.
10. Berl T, Verbalis J. Pathophysiology of water metabolism. In: Brenner BM, ed. Brenner & Rector's The Kidney, 7th edn. Amsterdam: Elsevier, 2004; 857-920.
11. Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu Rev Med 1993; 44:289-301.
12. Melton JE, Patlak CS, Pettigrew CD, Cserr HF. Volume regulatory loss of Na+, Cl-, and K+ from rat brain during acute hyponatremia. Am J Physiol 1987; 252 (4 Pt 2):F661-9.
13. Verbalis JG, Gullans SR. Hyponatremia causes large sustained reductions in brain content of multiple organic osmolytes in rats. Brain Res 1991; 567:274-82.
14. Verbalis JG, Gullans SR. Rapid correction of hyponatremia produces differential effects on brain osmolyte and electrolyte reaccumulation in rats. Brain Res 1993; 606:19-27.
15. Lien YH, Shapiro JI, Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia: implications for the pathogenesis of central pontine myelinolysis. J Clin Invest 1991; 88:303-9.
16. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986; 314:1535-42.
17. Butterworth RF. Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol 2003; 39:278-85.
18. Seery JP, Taylor-Robinson SD. The application of magnetic resonance spectroscopy to the study of hepatic encephalopathy. J Hepatol 1996; 25:988-98.
19. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 2002; 17:221-7.
20. Haussinger D, Laubenberger J, vom Dahl S et al. Proton magnetic resonance spectroscopy studies on human brain myoinositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 1994; 107:1475-80.
21. Restuccia T, Gómez-Ansón B, Guevera M et al. Effect of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 2004; 39:1613-22.
22. Córdoba J, Gottstein J, Blei AT. Chronic hyponatremia exacerbates ammonia-induced brain edema in rats after portacaval anastomosis. J Hepatol 1998; 29:589-94.
23. Ginès P, Berl T, Bernardi M et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28:851-64.
24. González FX, Rimola A, Grande L et al. Predictive factors of early postoperative graft function in human liver transplantation. Hepatology 1994; 20:565-73.
25. Estol CJ, Faris AA, Martinez AJ, Ahdab-Barmada M. Central pontine myelinolysis after liver transplantation. Neurology 1989; 39:496-8.
26. Wszolek ZK, McComb RD, Pfeiffer RF et al. Pontine and extrapontine myelinosis following liver transplantation. Relationship to serum sodium. Transplantation 1989; 48:1006-12.
27. Abbasoglu O, Goldstein RM, Vodapally MS et al. Liver transplantation in hyponatremic patients with the emphasis on central pontine myelinolysis. Clin Transplant 1998; 12:263-9.
28. Bronster DJ, Emre S, Boccagni P, Sheiner PA, Schwartz ME, Miller CM. Central nervous system complications in liver transplant recipients-incidence, timing, and long-term follow-up. Clin Transplant 2000; 14:1-7.
29. Gross P. Correction of hyponatremia. Semin Nephrol 2001; 21:269-72.
30. Gerbes AL, Gulberg V, Ginès P et al.; VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003; 124:933-9.
31. Cárdenas A, Ginès P. Pathogenesis and treatment of dilutional hyponatremia in cirrhosis. In: Arroyo V, Forns X, Garcia-Pagan JC, Rodés J, eds. Progress in the Treatment of Liver Diseases. Barcelona: Ars Medica, 2003; 31-42.
32. Perez-Ayuso RM, Arroyo V, Camps J et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26:72-80.
33. Ginès P, Titó L, Arroyo V et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94:1493-502.
34. DeTroyer A, Pilloy W, Broeckaert J, Demanet JD. Demeclocycline treatment of water retention in cirrhosis. Ann Intern Med 1976; 85:336-7.
35. Pérez-Ayuso RM, Arroyo V, Camps J et al. Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics. Nephron 1984; 36:30-3.
36. Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodés J. Renal failure associated with demeclocycline in cirrhosis. Ann Intern Med 1977; 87:195-7.
37. Decaux G, Mols P, Cauchie P, Flamion B, Delwiche F. Treatment of hyponatremic cirrhosis with ascites resistant to urea. Nephron 1986; 44:337-43.
38. Leander JD. Further study of kappa opioids in increased urination. J Pharmacol Exp Ther 1983; 227:35-41.
39. Bellissant E, Denolle T, Sinnassamy P et al. Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers. J Pharmacol Exp Ther 1996; 278:232-42.
40. Yamada K, Imai M, Yoshida S. Mechanism of diuretic action of U-62,066E, a kappa opioid receptor agonist. Eur J Pharmacol 1989; 160:229-37.
41. Blackburn TP, Borkowski KR, Friend J, Rance MJ. On the mechanisms of kappa-opioid-induced diuresis. Br J Pharmacol 1986; 89:593-8.
42. Bosch-Marcé M, Jiménez W, Angeli P et al. Aquaretic effect of the κ-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 1995; 109:217-23.
43. Moreau R, Cailmail S, Hamon G, Lebrec D. Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis. J Gastroenterol Hepatol 1996; 11:857-63.
44. Bosch-Marcé M, Poo JL, Jiménez W et al. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J Pharmacol Exp Ther 1999; 289:194-201.
45. Gadano A, Moreau R, Pessione F et al. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 2000; 32:38-42.
46. Sawyer WH, Pang PK, Seto J, McEnroe M, Lammec B, Manning M. Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 1981; 212:49-51.
47. Yamamura Y, Ogawa H, Yamashita H et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Phamacol 1992; 105:787-91.
48. Wong LL, Verbalis J. Vasopressin V2 receptor antagonists. Cardiovasc Res 2001; 51:391-402.
49. Fujisawa G, Ishikawa S, Tsuboi Y, Okada K, Saito T. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int 1993; 44:19-23.
50. Ohnishi A, Orita Y, Okahara R et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin V2 antagonist (OPC-31260) in men. J Clin Invest 1993; 92:2653-9.
51. Ohnishi A, Orita Y, Takagi N et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 1995; 272:546-51.
52. Saito T, Ishikawa S, Abe K et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997; 82:1054-7.
53. Serradeil-Le Gal C, Lacour C, Valette G et al. Characterization of SR121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996; 98:2729-38.
54. Epstein M, Orczky G, Muralidharan G, Fruncillo R. VPA-985: a novel non-peptide competitive vasopressin receptor antagonist for the treatment of dilutional hyponatremia. J Am Soc Nephrol 1998; 9:0544 (Abstract).
55. Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107:2690-6.
56. Burnier M, Fricker AF, Hayoz D, Nussberger J, Brunner HR. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 1999; 55:633-7.
57. Wada K, Tahara A, Arai Y et al. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. Eur J Pharmacol 2002; 450:169-77.
58. Tsukada J, Tahara A, Tomura Y et al. Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist. Eur J Pharmacol 2002; 446:129-38.
59. Clària J, Jiménez W, Arroyo V et al. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology 1989; 97:1294-9.
60. Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994; 46:237-44.
61. Jiménez W, Serradeil-le-Gal C, Ros J et al. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther 2000; 295:83-90.
62. Fernández-Varo G, Ros J, Cejudo-Martin P et al. Effect of the V1a/V2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol 2003; 38:755-61.
63. Inoue T, Ohnishi A, Matsuo A et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998; 63:561-70.
64. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002; 36:1197-205.
65. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37:182-91.